Clinical trial
A Phase 1 Study to Evaluate the Safety of DCC-2618 in Patients With Unresectable, Metastatic, or Recurrent Gastrointestinal Stromal Tumor (GIST) Who Are Refractory or Intolerant to at Least 3 Prior Therapies
NCT07618377 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety of DCC-2618 in Patients With Unresectable, Metastatic, or Recurrent Gastrointestinal Stromal Tumor (GIST) Who Are Refractory or Intolerant to at Least 3 Prior Therapies
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 7, 2026
- Completion date
- February 29, 2028
- Enrollment
- 10 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.